H Abdella1, M K Shaker1, Iman Fawzy Montasser2, M Sobhi3, H Aly1, A Sayed1, S Saleh4, A El Dorry3. 1. Departments of Tropical Medicine, Faculty of Medicine, Ain Shams University, Abbassia Square, Cairo, 11341, Egypt. 2. Departments of Tropical Medicine, Faculty of Medicine, Ain Shams University, Abbassia Square, Cairo, 11341, Egypt. imanfawzy2@gmail.com. 3. Radiodiagnosis and Intervention Radiology, Ain Shams University, Cairo, Egypt. 4. Internal Medicine, Ain Shams University, Cairo, Egypt.
Abstract
BACKGROUND/AIM: Portal vein tumor thrombosis (PVTT) is a common complication in hepatocellular carcinoma (HCC) and it was considered a relative contraindication for transarterial chemoembolization (TACE) by many centers. This study aimed to assess the outcomes after TACE in patients with branch PVT regarding Child classification, radiological response, and 1-year survival. METHODS: Thirty HCC patients (24 male, 6 females) Child A cirrhotics with branch PVT underwent TACE. Follow up was done at 1, 3, 6, and 12 months after first TACE. All patients underwent laboratory investigations including liver function tests to assess deterioration in liver functions and triphasic spiral computed tomography to assess radiological response according to modified response evaluation criteria in solid tumors (mRECIST) criteria, and survival analysis was recorded. RESULTS: TACE succeeded to achieve disease control in 93.3%, 86.3%, 57.7%, and 44.4% of patients after 1, 3, 6, and 12 months, respectively. Post-TACE liver decompensation occurred in the form of ascites in 30%, jaundice in 10%, and hepatic encephalopathy in 3.3% within 1 month of TACE. One month survival after TACE was 100%, 3 months was 96.6%, 6 months was 86.6%, and 1-year survival was 60%. Mean overall survival of the included patients was 17 months (SE = 1.59). CONCLUSION: TACE seems an alternative option for patients with unrespectable HCC with portal vein thrombosis in patients with good liver function tests.
BACKGROUND/AIM: Portal vein tumor thrombosis (PVTT) is a common complication in hepatocellular carcinoma (HCC) and it was considered a relative contraindication for transarterial chemoembolization (TACE) by many centers. This study aimed to assess the outcomes after TACE in patients with branch PVT regarding Child classification, radiological response, and 1-year survival. METHODS: Thirty HCC patients (24 male, 6 females) Child A cirrhotics with branch PVT underwent TACE. Follow up was done at 1, 3, 6, and 12 months after first TACE. All patients underwent laboratory investigations including liver function tests to assess deterioration in liver functions and triphasic spiral computed tomography to assess radiological response according to modified response evaluation criteria in solid tumors (mRECIST) criteria, and survival analysis was recorded. RESULTS:TACE succeeded to achieve disease control in 93.3%, 86.3%, 57.7%, and 44.4% of patients after 1, 3, 6, and 12 months, respectively. Post-TACE liver decompensation occurred in the form of ascites in 30%, jaundice in 10%, and hepatic encephalopathy in 3.3% within 1 month of TACE. One month survival after TACE was 100%, 3 months was 96.6%, 6 months was 86.6%, and 1-year survival was 60%. Mean overall survival of the included patients was 17 months (SE = 1.59). CONCLUSION:TACE seems an alternative option for patients with unrespectable HCC with portal vein thrombosis in patients with good liver function tests.
Authors: Jun Luo; Rong-Ping Guo; Eric C H Lai; Yao-Jun Zhang; Wan Yee Lau; Min-Shan Chen; Ming Shi Journal: Ann Surg Oncol Date: 2010-09-14 Impact factor: 5.344
Authors: Vincent James Cogliano; Robert Baan; Kurt Straif; Yann Grosse; Béatrice Lauby-Secretan; Fatiha El Ghissassi; Véronique Bouvard; Lamia Benbrahim-Tallaa; Neela Guha; Crystal Freeman; Laurent Galichet; Christopher P Wild Journal: J Natl Cancer Inst Date: 2011-12-12 Impact factor: 13.506
Authors: Sang Hoon Jeon; Kyung Sik Park; Young Hwan Kim; Yo Sig Shin; Min Kyoung Kang; Byoung Kuk Jang; Woo Jin Chung; Kwang Bum Cho; Jae Seok Hwang Journal: Korean J Gastroenterol Date: 2007-09
Authors: Jeong Il Yu; Sang Min Yoon; Hee Chul Park; Jong Hoon Kim; Tae Hyun Kim; Joong-Won Park; Jinsil Seong; Ik Jae Lee; Hong Seok Jang; Chul Seung Kay; Chul Yong Kim; Eui Kyu Chie; Jin Hee Kim; Mi-Sook Kim; Young Min Choi Journal: Cancer Res Treat Date: 2014-07-16 Impact factor: 4.679